Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Trial Profile

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms DAPA-HF
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Apr 2021 Results of a meta-analysis of DAPA-HF and EMPEROR-Reduced assessing composite renal endpoint regardless of presence of diabetes or baseline estimated glomerular filtration rate published in the Advances in Therapy
    • 09 Apr 2021 Results (n=2371) assessing efficacy of dapagliflozin on the predefined secondary endpoint of total failure hospitalizations (first and recurrent) and cardiovascular death, using a joint frailty model, published in the Circulation
    • 22 Feb 2021 Results of a post hoc analysis assessing the effect of dapagliflozin on correction of anaemia and the effect of dapagliflozin on outcomes, according to anaemia status at baseline in patients with heart failure and reduced ejection fraction published in the European Journal of Heart Failure
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top